Publications by authors named "Thomas Perretti"
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Leuk Lymphoma
May 2022
Article Synopsis
- A phase-II study evaluated the effectiveness and safety of atezolizumab combined with obinutuzumab in relapsed/refractory mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM), and with rituximab in marginal zone lymphoma (MZL).
- Objective response rates were 16.7% for MCL, 42.9% for MZL, and no responses for WM, with median response durations of 6.8 months for MCL and not reached for MZL.
- Treatment-emergent adverse events (TEAEs) were common across patient groups (93.3% in MCL, 95.2% in MZ
Background: Bevacizumab has been studied in numerous clinical trials in multiple types of cancer; however, patients may receive bevacizumab over an extended period of time. This study assessed the long-term safety and tolerability of bevacizumab among patients with solid tumors.
Materials And Methods: Patients enrolled in a Roche/Genentech-sponsored trial who had derived benefit from bevacizumab therapy as monotherapy or in combination with anticancer drugs were eligible for continuation of bevacizumab in this long-term extension (LTE) study.
The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first-line (1L; fit and non-fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analysis of the Phase IIIb GREEN trial (Clinicaltrials.gov: NCT01905943). The final analysis (cut-off, 31 January 2019) is reported here.
View Article and Find Full Text PDF